List of Excipients in Branded Drug TIGLUTIK

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Italfarmaco SPA	TIGLUTIK	riluzole	11797-210	DIMETHICONE
Italfarmaco SPA	TIGLUTIK	riluzole	11797-210	MAGNESIUM ALUMINUM SILICATE
Italfarmaco SPA	TIGLUTIK	riluzole	11797-210	POLYOXYL 20 CETOSTEARYL ETHER
Italfarmaco SPA	TIGLUTIK	riluzole	11797-210	SACCHARIN SODIUM
Italfarmaco SPA	TIGLUTIK	riluzole	11797-210	SILICON DIOXIDE

TIGLUTIK Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

TIGLUTIK is a 50 mg/10 mL riluzole oral suspension developed for patients with amyotrophic lateral sclerosis who have difficulty swallowing tablets. Its commercial value rests less on riluzole exclusivity than on the formulation, patient administration profile, dosing accuracy, and ability to address dysphagia in a chronic-use population.

The strongest commercial opportunities are lower-cost generic suspension products, improved enteral-tube compatibility, preservative-reduced formulations, more convenient packaging, and differentiated delivery systems that reduce administration errors.

What is TIGLUTIK and why does its formulation matter?

TIGLUTIK contains riluzole at a concentration of 5 mg/mL. The FDA approved the product in July 2018 under NDA 210326. The formulation is an oral suspension rather than a solution, which allows riluzole to be delivered in liquid form despite its limited aqueous solubility.[1]

TIGLUTIK addresses several practical limitations of riluzole tablets:

Attribute	TIGLUTIK profile
Active ingredient	Riluzole
Strength	50 mg/10 mL
Dosage form	Oral suspension
FDA indication	Amyotrophic lateral sclerosis
Standard adult dosing	50 mg twice daily
Primary patient need	Administration for patients with dysphagia
Administration requirement	Shake before use and measure with an oral syringe
Regulatory pathway	505(b)(2) NDA
Original FDA approval	July 18, 2018
Original sponsor	ITF Pharma, Inc.

For a 50 mg dose, the labeled volume is 10 mL. This creates a direct opportunity for competitors to improve dose-volume efficiency, syringe usability, bottle design, and caregiver administration.

What excipients are used in TIGLUTIK?

The TIGLUTIK formulation uses a conventional suspension architecture consisting of viscosity modifiers, wetting and dispersing components, sweeteners, pH-control agents, and antimicrobial preservatives. FDA labeling identifies excipients including glycerin, hypromellose, maltitol, microcrystalline cellulose and carboxymethylcellulose sodium, potassium sorbate, sodium benzoate, sodium citrate dihydrate, sucralose, and xanthan gum.[1]

How the principal excipients function

Excipient or excipient system	Formulation role	Commercial relevance
Microcrystalline cellulose and carboxymethylcellulose sodium	Structured suspension vehicle and sedimentation control	Supports dose uniformity after shaking
Xanthan gum	Suspending and viscosity-enhancing agent	Improves physical stability but can affect pourability and syringe performance
Hypromellose	Viscosity modification and particle suspension	May influence mouthfeel and redispersibility
Glycerin	Humectant, cosolvent, and mouthfeel modifier	Helps reduce grittiness and improves palatability
Maltitol	Bulk sweetener	Supports sugar-free positioning but may cause gastrointestinal effects at higher exposure
Sucralose	High-intensity sweetener	Masks bitterness from riluzole
Sodium citrate and citric acid-related buffering	pH control	Influences chemical stability, preservative performance, and taste
Sodium benzoate and potassium sorbate	Antimicrobial preservation	Supports multidose packaging and in-use stability

Riluzole is bitter and poorly suited to a simple aqueous liquid. The excipient system must therefore solve four linked problems: keep particles uniformly distributed, maintain chemical stability, reduce bitterness, and preserve the product after repeated opening.

What excipient strategy gives a competitor the strongest position?

The most defensible strategy is not a simple excipient substitution. A competitor would need to demonstrate a measurable improvement in stability, administration, tolerability, or manufacturing economics.

1. Improve suspension redispersibility

A suspension that settles rapidly creates dose-uniformity risk, particularly for elderly patients and caregivers. Excessive viscosity creates a different problem: incomplete withdrawal from an oral syringe, slow dosing, and residual product in the bottle.

Useful development targets include:

• Rapid redispersion after defined standing periods.
• Consistent dose delivery from the first through the last dose.
• Lower viscosity at the point of administration.
• Reduced sediment cake formation.
• Compatibility with both bottle pouring and oral-syringe withdrawal.

A formulation with better rheology could support a method-of-use or formulation patent if the performance advantage is linked to a defined excipient ratio or manufacturing process.

2. Reduce sugar-alcohol and preservative burden

TIGLUTIK uses maltitol and preservative agents. A competitor could pursue:

• A preservative-free single-dose presentation.
• A lower-maltitol formulation for patients with gastrointestinal sensitivity.
• A multidose product using a validated antimicrobial container-closure system.
• A formulation based on alternative sweetener combinations.
• A lower-sodium formulation for patients with dietary restrictions.

Preservative-free products would carry higher packaging costs but could command a premium in institutional, home-infusion, and specialty-pharmacy channels.

3. Improve taste and mouthfeel

Riluzole’s bitterness is a material adherence risk. Taste masking can be pursued through:

• Alternative sweetener systems.
• Ion-exchange resin complexes.
• Polymer-based taste-masking coatings.
• Lipid or multiparticulate encapsulation.
• Flavor systems designed for adult patients rather than pediatric medicines.

Taste masking must be balanced against suspension viscosity, particle size, syringe clogging, and dose uniformity. A formulation that tastes better but requires vigorous shaking or leaves a coating in the syringe may have limited commercial value.

4. Optimize enteral-tube delivery

ALS patients may require feeding tubes. Tube delivery creates technical requirements that are not fully addressed by an oral suspension label:

• No clogging through common tube sizes.
• Low residual volume.
• Rapid water flushability.
• No excessive adsorption to tubing.
• No significant dose loss during transfer.
• Stable exposure after dilution or flushing.

A tube-optimized riluzole suspension could target neurologists, home-care providers, hospitals, and specialty pharmacies. The strongest product would include validated administration instructions for commonly used tube sizes and flush volumes.

What patents protect TIGLUTIK?

TIGLUTIK’s commercial protection is expected to center on formulation and dosage-form patents rather than the riluzole molecule. Riluzole is an established active ingredient whose original compound protection expired years before TIGLUTIK’s approval.

Public FDA materials identify TIGLUTIK as a 505(b)(2) product. The approval relied on the known riluzole active ingredient while supporting the oral suspension dosage form through product-specific clinical and pharmaceutical data.[1][2]

Patent categories relevant to TIGLUTIK

Patent category	Relevance to TIGLUTIK	Generic challenge risk
Riluzole compound patent	Historical protection; no longer the principal barrier	Low
Oral suspension formulation patent	May cover excipient ratios, particle properties, or stability	Medium to high
Method-of-use patent	Could cover administration to ALS patients with swallowing impairment	Generally limited if indication is already known
Manufacturing patent	May cover milling, homogenization, suspension preparation, or filling	Medium
Container-closure patent	Could cover bottle, syringe, dosing cap, or multidose system	Low to medium
Trade-secret manufacturing process	May protect process parameters without appearing in the Orange Book	Difficult to assess from public records

A competitor should separate Orange Book-listed patents from unlisted process and device rights. An Orange Book patent can support a Paragraph IV certification and potential litigation. Unlisted manufacturing rights can still create supply and scale-up barriers, but they do not create the same statutory automatic stay under the Hatch-Waxman framework.

When did TIGLUTIK lose regulatory exclusivity?

TIGLUTIK did not receive new chemical entity exclusivity because riluzole was previously approved. Its regulatory exclusivity was therefore more limited than that of a new molecular entity.

The product’s likely three-year exclusivity period was tied to the new clinical investigations supporting the new dosage form and ran from the 2018 approval date. That period would have expired in 2021, subject to the exact FDA exclusivity code and approval record.[2]

TIGLUTIK also did not obtain a new seven-year orphan-drug exclusivity period merely because it introduced a new dosage form for ALS. Orphan exclusivity attaches to the approved drug for the designated disease or condition under specific statutory conditions; it does not automatically restart for every reformulation of an already approved active ingredient.[3]

What is the Orange Book status of TIGLUTIK?

TIGLUTIK is listed in FDA product databases as a prescription riluzole oral suspension. The Orange Book is the controlling source for current listed patents, exclusivity codes, therapeutic-equivalence information, and approved products.[2]

The practical regulatory issues for a generic or 505(b)(2) competitor are:

1. Whether any formulation patent remains listed against the TIGLUTIK NDA.
2. Whether an ANDA applicant can demonstrate pharmaceutical equivalence to the reference suspension.
3. Whether differences in excipients require a 505(b)(2) pathway rather than an ANDA.
4. Whether the reference product has an active exclusivity code that blocks approval.
5. Whether the proposed product can use the same labeling for tube administration, dosing devices, and storage.

A generic suspension with materially different excipients may face additional requirements for comparative dissolution, particle-size distribution, redispersibility, preservative effectiveness, microbial limits, and in-use stability.

What Paragraph IV challenges and litigation affect TIGLUTIK?

No settlement terms or active Paragraph IV outcome are identified in the FDA sources cited for this analysis. The litigation risk depends on the current Orange Book patent listing and any subsequent district-court filings.

A Paragraph IV strategy would be most credible against patents directed to:

• Broad excipient combinations.
• Generic suspension architecture.
• Riluzole particle-size ranges.
• Specific pH or viscosity windows.
• Stability claims.
• Manufacturing steps that are difficult to avoid.

A formulation patent with narrow performance limitations may be vulnerable to an invalidity or noninfringement challenge. A patent that claims a broad combination of common pharmaceutical excipients may face obviousness risk, particularly if the claimed ingredients perform predictable functions.

How strong is the TIGLUTIK patent estate?

The estate is likely moderate rather than molecule-level strong.

Strengths

• A liquid dosage form addresses a defined clinical problem.
• The formulation may require multiple interacting excipient functions.
• Suspension stability and dose uniformity can create meaningful development barriers.
• The product may have device and packaging dependencies.

Weaknesses

• Riluzole is an old active ingredient.
• Oral suspensions are established dosage forms.
• Many likely excipients are standard pharmaceutical materials.
• Generic applicants can design around individual excipient claims.
• Regulatory exclusivity from the 2018 approval is no longer the primary barrier.

The strongest protection would be a patent tied to an unexpected result, such as superior chemical stability, reduced degradation, improved tube delivery, or materially better dose uniformity from a defined formulation range.

What commercial opportunities exist for TIGLUTIK competitors?

The ALS market is relatively concentrated, but the administration problem is commercially meaningful. Riluzole tablets remain less suitable for patients with advanced dysphagia, while an oral suspension can support continued treatment in home settings.

Priority product concepts

Product concept	Target customer	Commercial potential
Lower-cost generic suspension	Payers and specialty pharmacies	High if patent barriers are cleared
Preservative-free unit-dose suspension	Hospitals and caregivers	Medium to high
Tube-optimized suspension	Advanced ALS and home-care patients	High clinical differentiation
Higher-concentration suspension	Caregivers and patients	Medium, subject to dose-error controls
Ready-to-administer prefilled syringe	Home-care and specialty channels	Medium
Improved taste formulation	Patients with adherence problems	Medium
Small-volume bottle and precision syringe	Specialty pharmacies	Medium
Stable formulation with reduced shaking requirement	Caregivers and institutional users	High usability value

Revenue exposure is difficult to isolate because public filings generally report broader product portfolios rather than TIGLUTIK sales separately. The addressable opportunity is therefore better assessed through prescription volume, payer reimbursement, pricing, and market share than through disclosed product revenue.

How does TIGLUTIK compare with other riluzole products?

Product	Dosage form	Main advantage	Main limitation
TIGLUTIK	Oral suspension	Designed for dysphagia and liquid administration	Multidose handling, shaking, preservative and stability requirements
Riluzole tablets	Tablet	Low cost and simple supply chain	Difficult for patients with swallowing impairment
Riluzole oral film products	Oral film	No water may be required; convenient administration	Different patient-use technique and product economics
Future generic suspension	Oral suspension	Potentially lower price and improved formulation	Must address patent, bioequivalence, and manufacturing risks

The relevant competitor is not only another riluzole suspension. Oral films and feeding-tube-compatible products can compete for the same dysphagia population even when they use a different delivery platform.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing risks are physical stability, microbial control, preservative effectiveness, and reproducible filling.

Critical process parameters include:

• Riluzole particle-size distribution.
• Wetting and dispersion sequence.
• Hydration time for cellulose and gum components.
• Mixing shear and homogenization.
• Final pH.
• Viscosity.
• Fill-volume accuracy.
• Bottle and syringe compatibility.
• In-use stability after repeated opening.

A technically simple formulation can still be difficult to scale. The suspension must remain uniform during filling, transport, storage, and repeated withdrawal. Process patents may cover a narrow preparation sequence even where the final excipient list appears conventional.

Key Takeaways

• TIGLUTIK is a 5 mg/mL riluzole oral suspension approved in 2018 for ALS patients who have difficulty swallowing.
• Its excipient strategy combines suspension polymers, sweeteners, pH-control agents, humectants, and preservatives.
• The principal commercial protection is formulation and dosage-form know-how, not riluzole molecule exclusivity.
• Regulatory exclusivity from the original approval was limited and is no longer the main market barrier.
• The strongest competitive opportunities are tube-compatible delivery, preservative-free packaging, improved taste, lower viscosity, and better dose uniformity.
• A generic developer must evaluate Orange Book formulation patents, 505(b)(2) versus ANDA eligibility, device rights, manufacturing patents, and supply-chain execution.
• The patent estate is likely moderate: technically meaningful but more vulnerable to design-around strategies than a new-molecule estate.

FAQs About TIGLUTIK Excipient Strategy and Market Entry

Can TIGLUTIK be reformulated without using the same excipients?

Yes. A competitor can use different excipients if it satisfies the applicable regulatory pathway and demonstrates equivalent performance, stability, dose uniformity, and safety. A material formulation change may require a 505(b)(2) application rather than a standard ANDA.

Is a preservative-free riluzole suspension commercially feasible?

Yes, but it would likely require unit-dose packaging, sterile or controlled manufacturing conditions, or a validated multidose container-closure system. The packaging cost would be higher than for a conventional preserved suspension.

Could a higher-concentration riluzole liquid compete with TIGLUTIK?

Potentially. A higher concentration could reduce administration volume, but it would increase the risk of dosing errors and may require new clinical, device, and stability data. It could also face formulation patent claims directed to concentration or suspension properties.

Are feeding-tube claims likely to provide meaningful patent protection?

They can if the product demonstrates unexpected advantages, such as reduced clogging, lower drug loss, or superior recovery after tube flushing. Generic tube-use claims based only on routine administration may be more vulnerable to obviousness challenges.

Does TIGLUTIK have biosimilar competition risk?

No. Riluzole is a small-molecule drug, so the relevant competitors are generic or 505(b)(2) products, not biosimilars. The principal risks are formulation patents, regulatory requirements, device compatibility, and manufacturing scale-up.

References

1. U.S. Food and Drug Administration. (2018). TIGLUTIK (riluzole) oral suspension prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. FDA.
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.